Job Description

The company operates on a hybrid working model to support cross-functional collaboration and development.

Short notice period will be preferred for this role.

Our company’s HTA & OR team is one of the largest and busiest teams in the UK. This is a leadership role within the team, offering profound development opportunities as well as making a meaningful difference to the patients’ and people’s lives by enabling national access to the company’s novel medicines and vaccines.

Our UK HTA team is responsible for submissions to NICE, SMC, AWMSG, and the JCVI, as well as supporting the Irish affiliate with NCPE submissions. We support regional and local access through the development of tools and resources for payer customers. We also lead and support appropriate evidence generation activities. The team is made up of health economists, evidence-based medicine managers, and real-world evidence generation experts.

A Team Lead at our company works within a global organisation, collaborating with colleagues around the world, to build and communicate the clinical and economic value of our company’s life-changing medicines. As a member of the HTA & OR team, you will be collaborating very closely with UK cross-functional colleagues, Global expert functions, as well as external stakeholders. Our company believes that cross-functional teamwork - always with patients in mind - is core to the success of the UK team, underpinning every project we do.

What you will do:

• National Value Assessment for Medicines and Vaccines
  • Devise coherent, therapy-area level HTA strategies necessary to optimise success in national value assessment processes while ensuring economic models support individual HTA strategies.
  • Supervise the development of high-quality and robust HTA dossiers and/or documents supportive of national vaccine tenders and JCVI review. Ensure the entirety of the value assessment process (clarification questions, ACD responses etc) is well-managed and all relevant stakeholders engaged, particularly ensuring clinical and patient experts are part of the decision-making process.
  • Ensure clear, concise, and coherent dossiers are produced, with regards both the clinical and economic sections, including the accurate description of the methods, assumptions, results, and uncertainties in the economic analysis.
  • Lead internal stakeholder engagement and communication at the therapy area level, within the UK and with global colleagues. Ensure quality and completeness of dossiers and projects for final signoff. Ensure all projects run to time, through robust project management across the therapy area.
  • Ensure outsourced projects are well managed, budgets tracked, and expectations are known as relate to necessary strategic and technical standards and timelines. Manage vendors providing UK deliverables, e.g., model adaptations, systematic literature reviews (SLR) and network meta-analyses (NMA) work.
  • Drive the global organisation’s pipeline preparation around trial designs, economic model development, evidence generation, evidence synthesis, and strategic positioning to ensure UK & Irish needs are accommodated.
  • Guide the development and design of UK cost-effectiveness and budget impact models for HTA submissions in line with high standards of accuracy, quality, and clinical relevance, reflective of the value proposition of the medicine.
  • Represent our company in various settings including NICE Technology Appraisal Committee meetings, scoping meetings, advisory boards, as required.
  • Identify solutions to technical challenges in the development of HTA submission strategies and respond to any challenges that emerge during the process.
  • Work with global and UK strategic pricing colleagues as required.
  • Communicate regularly with cross-functional teams on appraisal risks and opportunities. Solicit input and feedback to ensure alignment with key stakeholders, including patient groups and clinical experts.